Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+, Mozilla Firefox 20+, Internet Explorer 11, Opera 15–18, Apple Safari 7, SeaMonkey 2.15-2.23

Become a member
  1. OncologyPRO
  2. Meeting Resources
  3. ESMO Gynaecological Cancers Congress 2023

How to interpret overall survival data with PARP inhibitors

Why are we having this Symposium? Recent regulatory actions by FDA/EMEA regarding late-stage approval for PARPi in recurrent ovarian cancer

Date

23 Feb 2023

Session

How to interpret overall survival data with PARP inhibitors

Topics

Tumour Site

Ovarian Cancer

Presenters

Robert Coleman

Authors

R.L. Coleman

Author affiliations

  • US Oncology Research, The Woodlands/US

Resources

This content is available to ESMO members and event participants.
Login

Resources from the same session

Q&A

Presenter: All Speakers

Session: How to interpret overall survival data with PARP inhibitors

Resources:

Webcast

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings

  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.